【活動訊息】GeneNovate Investors' Day 2026
GeneNovate Investors' Day 2026
Date
June 9, 2026
Location
Berlin, Germany
Application Period
November 3, 2025 – January 16, 2026
About the Event
Following the success of its pilot edition in 2025, the GeneNovate Investors' Day returns in 2026 as a leading networking event for scientific project teams, international start-ups, investors, and experts from academia, industry, and policy.
The event highlights the rapidly advancing field of gene and cell therapies (GCT) and tissue-based therapeutics (Advanced Therapy Medicinal Products, ATMPs) — technologies that offer new hope for patients with rare diseases and treatment-resistant cancers. With the growing role of artificial intelligence (AI) across the value chain, the field is evolving faster than ever.
In Europe, sixteen gene therapies and one cell therapy have already been approved (as of December 2024), and global clinical activity continues to rise. Market forecasts predict up to €27.9 billion in revenue by 2026. Recognizing this potential, the German Federal Government has launched a National Strategy for Gene and Cell-Based Therapies to improve conditions for research, regulation, and manufacturing — with initiatives like the GeneNovate Entrepreneurship Program and dedicated networking platforms such as this Investors' Day.
Who Can Apply
Applications are open to:
- International start-ups and advanced academic projects focused on gene- and cell-based innovations
- Projects that are already founded or have a signed term sheet
Examples of eligible focus areas include:
◆ Somatic cell therapies (e.g., immune or stem cells, mesenchymal stromal cells)
◆ Gene therapies using viral/non-viral vectors or genome editing
◆ Tissue-engineered products and biomaterials
◆ Novel biologics such as mRNA or extracellular vesicles
◆ Companion diagnostics for advanced therapies
◆ Oncolytic virus-based or bacteria-based therapeutics
◆ Integration of AI for therapeutic target discovery, predictive modeling, manufacturing automation, and data-driven precision medicine
Your Benefits
Pitch Opportunity
Pitch opportunity at the GeneNovate Investors' Day on June 9, 2026
Direct Access
Direct access to leading investors and industry experts
Networking
Networking with peers and stakeholders shaping the future of advanced therapies
💡 Insights
Insights into value chain specifics, investment strategies, and international best practices